TWST Trading Analysis - 10/06/2026 02:59 PM — TRU-SENTIMENT

News Headlines & Context

Recent general-knowledge context for TWST (Twist Bioscience) suggests the following relevant themes that may frame the data-driven sections below:

• Twist Bioscience has been highlighted in prior periods for expanding its synthetic DNA and biopharma partner pipeline, often tied to AI-driven drug discovery demand.
• Sector coverage has noted elevated volatility in small-cap genomics names amid rising-rate sensitivity and profitless growth concerns.
• No specific confirmed earnings date is provided in the embedded data, but fiscal year end is listed as 2026-09-01, implying post-year-end reporting risk.
• Broader biotech sentiment has swung on regulatory and funding headlines, which can exacerbate TWST's high beta of 2.53.
• Contextual link to data: The embedded options flow is heavily bearish even as price tagged a 52-week high of 207.90 on 2026-10-05, hinting informed positioning may precede a news or earnings event.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for TWST:

• Trailing EPS is -2.23; the company is not profitable on a trailing basis (negative earnings).
• Trailing P/E is null and Forward P/E is null; PEG ratio is null — standard valuation multiples are not available, reflecting loss-making status.
• Revenue growth, gross/operating/net margins, ROE, and profit margins are all null in the data — no margin trend can be computed.
• Debt/Equity, Free Cash Flow, and total revenue are null — key solvency/strength metrics are absent from the feed.
• Institutional ownership is 98.11%, indicating heavy professional sponsorship despite losses.
• Market cap is 11.37B with 66.30M shares outstanding; dividend yield is 0.00% (no income).
• 52-week range is 23.30 to 207.90 — extreme expansion from lows; current price near top of range.
• Beta is 2.53 and historical volatility is 76.04%, confirming high-risk profile.
• Analyst consensus and target mean price are null — no street target context provided.

Fundamentals diverge from the technical picture: price surged to 207.71 (2026-10-05) on momentum, yet EPS is negative and valuation anchors are missing. The data shows a speculative, institutional-driven name with no earnings support in the embedded fundamentals.

Current Market Position

From the embedded MINUTE and DAILY data:

• Daily close on 2026-10-05 was 207.71; intraday that day ranged 189.25 to 207.90 (new 52-week high per fundamentals).
• Minute bars show 2026-10-05 opened 193.46 and climbed to 199.53 by 09:50; last bars on 2026-10-06 show decay to 172.00 by 14:30 (low 172.00).
• Two-session shift: from 207.71 close to ~172.00 live — a drop of roughly 35.71 points (-17.20%).
• Minute-volume on 2026-10-06 14:10 was 53,100 then easing; consistent with distribution into weakness.

Technical Analysis

• SMA alignment: 5 (193.33) > 20 (162.40) > 50 (138.12) — bullish stack, but price extended above SMA 5.
• RSI 14 at 82.99 is overbought (above 70 threshold), signalling exhaustion risk.
• MACD 17.92 > signal 14.33, histogram +3.58 — positive momentum yet flattening potential.
• Bollinger: price 207.71 near upper 213.63 — expansion, not squeeze; upper band caps near-term.
• 30-day range: price at 207.90 high end; 120.19 low is 87.71 points below — extreme positioning.

True Sentiment Analysis (Delta 40-60 Options)

From the TRUE SENTIMENT OPTIONS file (2026-10-06 14:58):

Call Dollar Volume: 2,181,380.00 (22.70%) Put Dollar Volume: 7,429,960.00 (77.30%) Total: 9,611,340.00

• Overall sentiment: Bearish per methodology (Delta 40-60 only).
• Put contracts 3,326 vs call 1,158; put trades 18 vs call 27 — size skews defensive.
• Pure directional conviction suggests near-term downside protection / bearish bets into 11-20 expiry.
• Divergence: technicals show overbought bullish stack, but options flow is 77.30% put-dollar — clear disconnect.

Key Price Levels (Observational Only)